[China BD 2025] Lepu Biopharma and ArriVent enters a 1.2 billion USD License on CDH17 ADC MRG007

Announced Date: 2025-01-22 (January 22, 2025)

Licensor (Seller): Lepu Biopharma (China)

Licensee (Buyer): ArriVent BioPharma (US)

.

Asset Name: MRG007

Asset Modality: ADC (antibody drug conjugate) 

Asset Target: CDH17

Potential Indication: Gastrointestinal (“GI”) Cancers

Current Stage: IND enabling studies

.

Scope of Authority:  

Lepu Biopharma has granted ArriVent exclusive rights to develop, manufacture and commercialize MRG007 outside of Greater China which includes mainland China, Hong Kong, Macau and Taiwan.

.

Payment Detail:

Upfront payment and Near-term payment of $47 million,

Milestone payments up to  $1.16 billion.

Tiered royalties on net sales outside of Greater China.

.

Link:

Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the treatment of Gastrointestinal Cancers

.

Note:

Chinese Name of Lepu Biopharma, 乐普生物